Acadia Pharmaceuticals (ACAD) Market Capitalization (2010 - 2026)

Acadia Pharmaceuticals has reported Market Capitalization for 17 years, with the latest figure at $4.4 billion in Q2 2026.

• On a quarterly basis, Market Capitalization rose 19.74% year-over-year to $4.4 billion in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 19.74% increase from a year earlier, with the FY2025 full-year figure at $4.5 billion, up 48.7% from the prior year.
• Market Capitalization was $4.4 billion for Q2 2026 at Acadia Pharmaceuticals, up from $3.8 billion in the prior quarter.
• The five-year high for Market Capitalization was $5.2 billion in Q4 2023, with the low at $2.3 billion in Q2 2022.
• Average Market Capitalization over 5 years is $3.4 billion, with a median of $3.2 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Market Capitalization slumped 41.79% in 2022, then soared 99.81% in 2023.
• Over 5 years, Market Capitalization stood at $2.6 billion in 2022, then surged by 99.81% to $5.2 billion in 2023, then plunged by 40.66% to $3.1 billion in 2024, then soared by 48.7% to $4.5 billion in 2025, then decreased by 4.26% to $4.4 billion in 2026.
• The last three Market Capitalization figures came in at $4.4 billion (Q2 2026), $3.8 billion (Q1 2026), and $4.5 billion (Q4 2025), per Business Quant data.